Application for production of flupentine maleate capsule

According to the website of the State Food and Drug Administration (CFDA) on April 2, HongRi pharmaceutical declared to produce six kinds of new chemical drugs - flupentine maleate capsules, and the distribution of varieties expanded to the field of painkillers In November 2013, the company's application for the production of flupentine maleate API has been accepted The API is a class III new drug At that time, the company's insiders disclosed that "the preparation will be applied together" To this day, the preparation has finally been accepted by the SFDA Flupentine maleate is a new type of non opioid analgesics Its acting agent is a selective potassium channel opener, which has three functions of analgesics, muscle relaxation and nerve protection Compared with the narcotic analgesics represented by morphine and the antipyretic analgesics represented by aspirin, there were no adverse reactions such as addiction and gastrointestinal symptoms According to the public information, in September 2006, China approved the import of flupentine maleate capsule (trade name "Kodak dragon") from AWD company of Germany, but no domestic enterprise has yet produced it According to CFDA, 10 enterprises including Enhua Pharmaceutical (002262 SZ), Suzhou Erye and Nanjing Haichen are applying for the production of this kind of API and capsule at the same time The main products of HongRi pharmaceutical are Xuebijing injection, fasudil hydrochloride injection and low molecular weight heparin calcium injection, which are all concentrated in the field of cardio cerebral vascular; meanwhile, the traditional Chinese medicine formula granules are another focus of the company The application for production approval of flupentine maleate aims to open up the field of painkillers.